<HashMap><database>biostudies-arrayexpress</database><scores/><additional><omics_type>Metabolomics</omics_type><omics_type>Unknown</omics_type><omics_type>Transcriptomics</omics_type><omics_type>Genomics</omics_type><omics_type>Proteomics</omics_type><submitter>Helen Parker</submitter><study_type>methylation profiling by array</study_type><organism>Homo species</organism><species>Homo species</species><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/E-MTAB-15593</full_dataset_link><description>High genomic complexity (HGC) is linked to poor prognosis in chronic lymphocytic leukaemia (CLL), but its independent prognostic value remains uncertain amid emerging biomarkers. Therefore we analysed copy number alterations in 495 treatment-naïve patients from three randomized trials (CLL4, ADMIRE, ARCTIC), incorporating IGHV status, telomere length (TL), targeted sequencing, and DNA-methylation subtypes.</description><repository>biostudies-arrayexpress</repository><sample_protocol>Labeling - Bisulphite treatment</sample_protocol><sample_protocol>Hybridization - Infinium assay</sample_protocol><sample_protocol>Scaning - RnBeads v2.93</sample_protocol><sample_protocol>Nucleic Acid Extraction - Qiagen DNeasy column extraction</sample_protocol><sample_protocol>Sample Collection - peripheral blood mononuclear cell sample taken by venipuncture</sample_protocol><figure_sub>MIAME Score</figure_sub><figure_sub>Raw Data</figure_sub><figure_sub>Organization</figure_sub><figure_sub>Assays and Data</figure_sub><figure_sub>MAGE-TAB Files</figure_sub><figure_sub>Array Designs</figure_sub><pubmed_authors>Helen Parker</pubmed_authors></additional><is_claimable>false</is_claimable><name>Copy number profiling of Chronic lymphocytic leukaemia patients</name><description>High genomic complexity (HGC) is linked to poor prognosis in chronic lymphocytic leukaemia (CLL), but its independent prognostic value remains uncertain amid emerging biomarkers. Therefore we analysed copy number alterations in 495 treatment-naïve patients from three randomized trials (CLL4, ADMIRE, ARCTIC), incorporating IGHV status, telomere length (TL), targeted sequencing, and DNA-methylation subtypes.</description><dates><release>2026-04-01T00:00:00Z</release><modification>2026-04-02T01:05:06.523Z</modification><creation>2025-09-12T12:47:50.194Z</creation></dates><accession>E-MTAB-15593</accession><cross_references><EFO>EFO_0002944</EFO><EFO>EFO_0003814</EFO><EFO>EFO_0003813</EFO><EFO>EFO_0002759</EFO><EFO>EFO_0005518</EFO><EFO>EFO_0003815</EFO></cross_references></HashMap>